Integral Diagnostics (IDX) H1 2026 earnings summary

Executive summary

• Revenue grew 55.6% year-over-year to AUD 393.5 million for 1H FY26, driven by the Capitol merger/acquisition and organic growth.

• Operating EBITDA increased 75.6% to AUD 81.1 million, with margin improving to 20.6% (up 230bps year-over-year).

• Operating NPAT rose 154.6% to AUD 22.3 million; Operating diluted EPS up 66.2% to 5.9 cps.

• Interim dividend per share increased 32% to 3.3 cps.

• Capitol merger integration well advanced, with annual synergies exceeding AUD 14 million.

Financial highlights

• Revenue: AUD 393.5 million (up 55.6% year-over-year), including six months of Capitol contribution.

• Operating EBITDA: AUD 81.1 million (up 75.6%), margin 20.6%.

• Operating NPAT: AUD 22.3 million (up 154.6%).

• Operating free cash flow: AUD 35.8 million (up 64.5%).

• Interim dividend per share: 3.3 cps (up 32%).

Outlook and guidance

• FY26 operating EBITDA margin forecast around 21%, supported by new site ramp-ups and procurement efficiencies.

• Revenue growth expected to continue, with January 2026 constant currency revenue growth at 7.8%.

• CapEx for FY26 expected between AUD 45 million and AUD 55 million.

• Net debt to EBITDA projected to trend down further over time.

• Focus on organic earnings growth, radiologist recruitment, operational efficiency, and digital/AI adoption.